A Study of LY3502970 in Healthy Participants
第1相
完了
NCT03929744
| 対象疾患 | Healthy |
|---|
| 相 | 第1相 |
|---|
| スポンサー | Eli Lilly and Company |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 133 名 |
|---|
| 介入（薬剤） | LY3502970, Atorvastatin, Simvastatin, Midazolam |
|---|
| 開始日 | 2019年6月12日 |
|---|
| 完了日 | 2020年11月2日 |
|---|
| 結果公開日 | 2026年7月10日 |
|---|
概要
The main purposes of this study are to determine: * The safety of LY3502970 and any side effects that might be associated with it. * How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.
Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
Baseline through Follow-up (up to Day 42) · Participants
| Part A Placebo | 0 Participants |
|---|
| Part A 0.3 mg LY3502970 | 0 Participants |
|---|
| Part A 1 mg LY3502970 | 0 Participants |
|---|
| Part A 3 mg LY3502970 | 0 Participants |
|---|
| Part A 6 mg LY3502970 | 0 Participants |
|---|
| Part B Placebo | 0 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。